Teva Pharmaceutical Industries (TEVJF) FCF Margin (2017 - 2026)

Teva Pharmaceutical Industries has disclosed FCF Margin across 10 years of filings, most recently posting 5.22% for Q1 2026.

• Quarterly FCF Margin rose 74.0% year-over-year to 5.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.76% (up 175.0% YoY) and the FY2025 annual result came in at 6.65%, up 212.0% from the prior year.
• FCF Margin declined to 5.22% in Q1 2026, from 21.57% in the prior quarter.
• Over five years, FCF Margin peaked at 23.89% in Q4 2023 and troughed at 7.76% in Q1 2023.
• A 5-year average of 5.02% and a median of 3.14% in 2025 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2023 — FCF Margin slumped 1545 bps — and 2024, when it jumped 1632 bps.
• Tracing TEVJF's FCF Margin over 5 years: stood at 21.4% in 2022, then increased by 12 bps to 23.89% in 2023, then sank by 36 bps to 15.38% in 2024, then surged by 40 bps to 21.57% in 2025, then sank by 124 bps to 5.22% in 2026.
• Business Quant data shows TEVJF's FCF Margin at 5.22% in Q1 2026, 21.57% in Q4 2025, and 5.2% in Q3 2025.